← All trials
NCT05614245
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2023
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Nov 14, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 60
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- VBI Vaccines Inc.Lead sponsor
- University of OttawaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.